Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

Abstract

Danoprevir was safe and well tolerated when administered for 14 days in patients with chronic HCV genotype 1 infection.

Treatment resulted in sustained, multi-log(10) IU/ml reductions in HCV RNA in upper dose cohorts.

These results support further clinical evaluation of danoprevir in patients with chronic HCV.

Full Text

• DOI - Journal of Hepatology (DOI)
• Swets Information Services - full-text online
• OhioLINK Electronic Journal Center - full-text online
• Elsevier Science - full-text online
• EBSCO - full-text online

Subjects

• Adult
• Aged
• Alanine Transaminase
• Antiviral Agents
• Carrier Proteins
• Double-Blind Method
• Drug Resistance, Viral
• Female
• Hepacivirus
• Hepatitis C, Chronic
• Humans
• Interferon Alfa-2a
• Lactams
• Male
• Middle Aged
• Polyethylene Glycols
• RNA, Viral
• Ribavirin
• Serine Proteinase Inhibitors
• Sulfonamides
• Viral Load
• Viral Nonstructural Proteins

Similar articles

• Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. (2011-12-27)
• Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. (2011-06-28)
• Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. (2011-10-19)
• Optimizing hepatitis C therapy in HIV/hepatitis C virus (HCV) coinfected patients: Analysis of HCV viral kinetics on treatment. (2013-03-01)
• Marked increase of serum hepatitis C virus (HCV) RNA titer during treatment with high-dose prednisolone in a case of polymyositis. (2005-04-08)
• Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. (2013-03-27)
• Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. (2004-04-01)
• Antiviral Activity of Boceprevir Monotherapy in Treatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3. (2013-02-27)
• Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. (2003-10-22)

Authors

• Nicole Forestier
• Dominique Larrey
• Dominique Guyader
• Patrick Marcellin
• Régine Rouzier
• Alain Patat
• Patrick Smith
• Williamson Bradford
• Steven Porter
• Lawrence Blatt
• Scott D Seiwert
• Stefan Zeuzem

Publication date

2011-05-20

Journal

Journal topics

• Liver
• Liver Diseases

Language

Eng.

Copyright

Journal of Hepatology

J.W. Goethe Universität, Frankfurt, Germany. nicole.forestier [at] kgu.de

Release reference

J Hepatol. 2011 Jun;54(6):1130-6

Related books

• Books of Alanine Transaminase
• Books of Antiviral Agents
• Books of Carrier Proteins
• Books of Double-Blind Method
• Books of Drug Resistance, Viral
• Books of Hepacivirus
• Books of Hepatitis C, Chronic
• Books of Interferon Alfa-2a
• Books of Lactams
• Books of Liver
• Books of Liver Diseases
• Books of Polyethylene Glycols
• Books of RNA, Viral
• Books of Ribavirin
• Books of Serine Proteinase Inhibitors
• Books of Sulfonamides
• Books of Viral Load
• Books of Viral Nonstructural Proteins